Biotech innovator Alumis, focused on autoimmune therapies, reported a significant insider buy amid a year of robust stock ...

The dispute involved additions of partners capital treated as unexplained cash credits. The Tribunal did not rule on merits but remanded the matter due to procedural violation by the appellate ...